<DOC>
	<DOC>NCT00034359</DOC>
	<brief_summary>The purpose of this study is to determine the safety and anti-HBV activity of ACH-126, 443 (beta-L-Fd4C) in comparison to lamivudine or placebo in treatment naive adults with chronic Hepatitis B infection.</brief_summary>
	<brief_title>Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description>Evaluation of safety and antiviral activity of 3 dose levels of ACH-126, 443 vs. lamivudine and placebo over 12 weeks of treatment in the population described.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adults &gt;= 18 years of age Chronic HBV infection, known to be HbsAg positive &gt;= 6 months Plasma HBV DNA level &gt;= 100,000 copies/mL HBeantigen positive HIV negative Basic hematologic and chemistry parameters within acceptable limits (defined in protocol No need for excluded medications Subjects of reproductive capability must utilize two approved forms of birth control, one of which must be barrier protection. HIV infection Hepatitis C coinfection Concurrent systemic antiviral treatment Previous antiviral treatment for HBV infection within 6 months prior to randomization or treatment with 3TC for more than 6 months at any time in the past Previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start Alcohol abuse Pregnancy or breastfeeding Inability to tolerate oral medication AST&gt;7.0 times the upper limit of normal ALT&gt;7.0 times the upper limit of normal Any clinical condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements Use of any investigational drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>E-antigen positive</keyword>
	<keyword>Treatment Naive Chronic Hepatitis B, Achillion</keyword>
</DOC>